Literature DB >> 25642318

Targeting precision medicine toxicity: recent developments.

Gordon Mallarkey1, Arduino A Mangoni2.   

Abstract

Entities:  

Year:  2015        PMID： 25642318      PMCID： PMC4308411          DOI： 10.1177/2042098614560737

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN： 2042-0986


× No keyword cloud information.
  40 in total

Review 1.  Drug-induced interstitial lung disease in molecular targeted therapies: high-resolution CT findings.

Authors:  Fumikazu Sakai; Takeshi Johkoh; Masahiko Kusumoto; Hiroaki Arakawa; Masahiro Takahashi
Journal:  Int J Clin Oncol       Date:  2012-11-10       Impact factor: 3.402

2.  Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment.

Authors:  Charlotte Pawlyn; Mohid S Khan; Ann Muls; Priya Sriskandarajah; Martin F Kaiser; Faith E Davies; Gareth J Morgan; H Jervoise N Andreyev
Journal:  Blood       Date:  2014-10-09       Impact factor: 22.113

Review 3.  Guidance on the management of diarrhoea during cancer chemotherapy.

Authors:  Jervoise Andreyev; Paul Ross; Clare Donnellan; Elaine Lennan; Pauline Leonard; Caroline Waters; Linda Wedlake; John Bridgewater; Rob Glynne-Jones; William Allum; Ian Chau; Richard Wilson; David Ferry
Journal:  Lancet Oncol       Date:  2014-09       Impact factor: 41.316

4.  Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.

Authors:  Francesca Toffalorio; Gianluca Spitaleri; Chiara Catania; Laura Dal Zotto; Cristina Noberasco; Angelo Delmonte; Mariacarmela Santarpia; Fabio Vecchio; Veronica Brunelli; Cristiano Rampinelli; Massimo Barberis; Caterina Fumagalli; Massimo Zucchetti; Monique Zangarini; Tullia Diena; Romano Danesi; Filippo de Braud; Tommaso De Pas
Journal:  Oncologist       Date:  2014-03-27

5.  Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

Authors:  Julie R Brahmer; Charles G Drake; Ira Wollner; John D Powderly; Joel Picus; William H Sharfman; Elizabeth Stankevich; Alice Pons; Theresa M Salay; Tracee L McMiller; Marta M Gilson; Changyu Wang; Mark Selby; Janis M Taube; Robert Anders; Lieping Chen; Alan J Korman; Drew M Pardoll; Israel Lowy; Suzanne L Topalian
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

6.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

7.  A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.

Authors:  I Chau; A R Norman; D Cunningham; D Tait; P J Ross; T Iveson; M Hill; T Hickish; F Lofts; D Jodrell; A Webb; J R Oates
Journal:  Ann Oncol       Date:  2005-02-02       Impact factor: 32.976

8.  Phase I/II trial of tremelimumab in patients with metastatic melanoma.

Authors:  Luis H Camacho; Scott Antonia; Jeffrey Sosman; John M Kirkwood; Thomas F Gajewski; Bruce Redman; Dmitri Pavlov; Cecile Bulanhagui; Viviana A Bozon; Jesus Gomez-Navarro; Antoni Ribas
Journal:  J Clin Oncol       Date:  2009-01-12       Impact factor: 44.544

9.  Phase I/II study of ipilimumab for patients with metastatic melanoma.

Authors:  Jeffrey S Weber; Steven O'Day; Walter Urba; John Powderly; Geoff Nichol; Michael Yellin; Jolie Snively; Evan Hersh
Journal:  J Clin Oncol       Date:  2008-11-17       Impact factor: 44.544

10.  Effectiveness and tolerability of colesevelam hydrochloride for bile-acid malabsorption in patients with cancer: a retrospective chart review and patient questionnaire.

Authors:  Linda Wedlake; Karen Thomas; Amyn Lalji; Constantinos Anagnostopoulos; H Jervoise N Andreyev
Journal:  Clin Ther       Date:  2009-11       Impact factor: 3.393
View more
  3 in total

Review 1.  Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.

Authors:  Adil Daud; Katy Tsai
Journal:  Oncologist       Date:  2017-05-18

2.  Adverse Event Management in Patients with BRAF V600E-Mutant Non-Small Cell Lung Cancer Treated with Dabrafenib plus Trametinib.

Authors:  Anna Chalmers; Laura Cannon; Wallace Akerley
Journal:  Oncologist       Date:  2018-12-31

Review 3.  Cardio-Oncology: Cancer Therapy-related Cardiovascular Complications in a Molecular Targeted Era: New Concepts and Perspectives.

Authors:  David Hurtado-de-Mendoza; Arturo Loaiza-Bonilla; Paula A Bonilla-Reyes; Gabriel Tinoco; Rodrigo Alcorta
Journal:  Cureus       Date:  2017-05-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.